Merit Medical Acquires View Point Medical for $140M to Expand Oncology Portfolio
Merit Medical Systems has acquired View Point Medical for approximately $140m, including $90m paid in cash at closing and two $25m deferred payments. The deal adds the FDA-cleared OneMark detection imaging system to Merit's portfolio and is expected to contribute $2m-$4m in 2026 revenue and be accretive in 2027.
1. Acquisition Terms
Merit Medical Systems acquired View Point Medical for a total consideration of approximately $140 million, including $90 million in cash paid at closing and two $25 million deferred payments due on the first and second anniversaries of the transaction.
2. Product Integration and Portfolio Expansion
View Point’s OneMark detection imaging system and ultrasound-enhanced tissue markers will become part of Merit’s SCOUT platform, enhancing the company’s therapeutic oncology offerings by improving lesion localization during biopsy and potentially reducing additional marking procedures.
3. Financial Impact and Guidance
Merit projects the acquisition will add $2 million to $4 million in revenue from April to December 2026 and lower non-GAAP earnings per share by $0.05 in the same period. For the full year ending December 2027, revenue contributions are expected at $14 million to $16 million and become accretive to non-GAAP EPS.
4. Strategic Rationale
The acquisition addresses an estimated 1.3 million annual breast and soft tissue tumor localization procedures in the U.S., supporting Merit’s growth strategy in therapeutic oncology and expanding its footprint in high-impact interventional devices.